THAR Valuation
Tharimmune Inc
$
4.150
THAR Relative Valuation
THAR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, THAR is overvalued; if below, it's undervalued.
Historical Valuation
Tharimmune Inc (THAR) is now in the Fair zone, suggesting that its current forward PS ratio of 3.99 is considered Fairly compared with the five-year average of -0.75. The fair price of Tharimmune Inc (THAR) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：4.15
Fair
-0.57
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Tharimmune Inc. (THAR) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-1.49
EV/EBIT
Tharimmune Inc. (THAR) has a current EV/EBIT of -1.49. The 5-year average EV/EBIT is -0.27. The thresholds are as follows: Strongly Undervalued below -2.18, Undervalued between -2.18 and -1.23, Fairly Valued between 0.69 and -1.23, Overvalued between 0.69 and 1.65, and Strongly Overvalued above 1.65. The current Forward EV/EBIT of -1.49 falls within the Undervalued range.
3.99
PS
Tharimmune Inc. (THAR) has a current PS of 3.99. The 5-year average PS is 0.02. The thresholds are as follows: Strongly Undervalued below -0.49, Undervalued between -0.49 and -0.23, Fairly Valued between 0.27 and -0.23, Overvalued between 0.27 and 0.53, and Strongly Overvalued above 0.53. The current Forward PS of 3.99 falls within the Strongly Overvalued range.
0.00
P/OCF
Tharimmune Inc. (THAR) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Tharimmune Inc. (THAR) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Tharimmune Inc (THAR) has a current Price-to-Book (P/B) ratio of 45.85. Compared to its 3-year average P/B ratio of 4.24 , the current P/B ratio is approximately 980.48% higher. Relative to its 5-year average P/B ratio of 3.33, the current P/B ratio is about 1275.95% higher. Tharimmune Inc (THAR) has a Forward Free Cash Flow (FCF) yield of approximately -41.31%. Compared to its 3-year average FCF yield of -219.37%, the current FCF yield is approximately -81.17% lower. Relative to its 5-year average FCF yield of -178.77% , the current FCF yield is about -76.89% lower.
45.85
P/B
Median3y
4.24
Median5y
3.33
-41.31
FCF Yield
Median3y
-219.37
Median5y
-178.77
Competitors Valuation Multiple
The average P/S ratio for THAR's competitors is 2.37, providing a benchmark for relative valuation. Tharimmune Inc Corp (THAR) exhibits a P/S ratio of 3.99, which is 68.41% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of THAR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of THAR in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Tharimmune Inc (THAR) currently overvalued or undervalued?
Tharimmune Inc (THAR) is now in the Fair zone, suggesting that its current forward PS ratio of 3.99 is considered Fairly compared with the five-year average of -0.75. The fair price of Tharimmune Inc (THAR) is between to according to relative valuation methord.
What is Tharimmune Inc (THAR) fair value?
How does THAR's valuation metrics compare to the industry average?
What is the current P/B ratio for Tharimmune Inc (THAR) as of Nov 07 2025?
What is the current FCF Yield for Tharimmune Inc (THAR) as of Nov 07 2025?
What is the current Forward P/E ratio for Tharimmune Inc (THAR) as of Nov 07 2025?